Severe Plaque Psoriasis
Showing 1 - 25 of >10,000
Tolerability in Pediatric Patients With Psoriasis
Not yet recruiting
- Moderate-to-severe Plaque Psoriasis
- Secukinumab
- (no location specified)
Nov 16, 2023
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis Trial (Placebo, Bimekizumab)
Not yet recruiting
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
- Placebo
- Bimekizumab
- (no location specified)
Aug 21, 2023
Moderate-to-severe Plaque Psoriasis Patients Response to
Completed
- Moderate-to-severe Plaque Psoriasis
-
Jakarta, IndonesiaMangga Besar Clinic
Mar 15, 2023
Deucravacitinib in Moderate-to-Severe Plaque Psoriasis in
Recruiting
- Plaque Psoriasis
-
Selters, Rhineland-Palatinate, GermanyDermatologische Spezial- und Schwerpunktpraxis Selters
Oct 23, 2023
Plaque Psoriasis Trial in Karachi (Secukinumab Injection)
Completed
- Plaque Psoriasis
- Secukinumab Injection
-
Karachi, Sindh, PakistanJinnah Post graduate Medical centre
Jun 4, 2023
Psoriasis Trial in Shanghai (HS-10374 tablets 1mg, HS-10374 tablets 5mg, HS-10374-matched tablets)
Not yet recruiting
- Psoriasis
- HS-10374 tablets 1mg
- +2 more
-
Shanghai, Shanghai, ChinaHuashan Hospital of Fudan University
Oct 8, 2023
Plaque Psoriasis Trial in Pembroke Pines (TLL018 tablets)
Recruiting
- Plaque Psoriasis
- TLL018 tablets
-
Pembroke Pines, FloridaAQUA - Riverchase
Mar 6, 2023
Effects, Drug Side Trial in Shanghai (Placebo, SYHX1901)
Recruiting
- Effects, Drug Side
- Placebo
- SYHX1901
-
Shanghai, Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
May 4, 2023
Moderate-to-Severe Plaque Psoriasis Trial in Shenyang (Jaktinib, Placebo)
Recruiting
- Moderate-to-Severe Plaque Psoriasis
- Jaktinib
- Placebo
-
Shenyang, Liaoning, ChinaThe First Affiliated Hospital of China Medical University
Nov 28, 2022
Clinical Study of Stage IV Psoriasis in Children With Geleli
Not yet recruiting
- Plaque Psoriasis
- (no location specified)
Mar 26, 2023
Psoriasis Trial in Shanghai (IBI112, /IBI112)
Not yet recruiting
- Psoriasis
- IBI112
- placebo /IBI112
-
Shanghai, Shanghai, ChinaShanghai Skin Disease Hospital
Dec 1, 2022
Psoriasis Trial in Beijing (IBI112 dose 2, IBI112 dose 4, IBI112 dose 1)
Active, not recruiting
- Psoriasis
- IBI112 dose 2
- +4 more
-
Beijing, Beijing, ChinaPeKing University People's Hostpital
Jan 20, 2023
Healthcare Resource Utilization Among Adult Moderate-To-Severe
Not yet recruiting
- Psoriasis
-
Nanjing, Jiangsu, ChinaLocal Institution
Sep 16, 2022
Plaque Psoriasis Trial in Hangzhou (BAT2206, Stelara (EU-sourced))
Active, not recruiting
- Plaque Psoriasis
- BAT2206
- Stelara (EU-sourced)
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University School of
Aug 18, 2022
